Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 25;25(3):1456.
doi: 10.3390/ijms25031456.

New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma-Today and Tomorrow

Rafał Becht  1 , Kajetan Kiełbowski  1 , Michał P Wasilewicz  2
Affiliations
Review

New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma-Today and Tomorrow

Rafał Becht et al. Int J Mol Sci. .

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Liver cirrhosis, hepatitis B, hepatitis C, and non-alcoholic fatty liver disease represent major risk factors of HCC. Multiple different treatment options are available, depending on the Barcelona Clinic Liver Cancer (BCLC) algorithm. Systemic treatment is reserved for certain patients in stages B and C, who will not benefit from regional treatment methods. In the last fifteen years, the arsenal of available therapeutics has largely expanded, which improved treatment outcomes. Nevertheless, not all patients respond to these agents and novel combinations and drugs are needed. In this review, we aim to summarize the pathway of trials investigating the safety and efficacy of targeted therapeutics and immunotherapies since the introduction of sorafenib. Furthermore, we discuss the current evidence regarding resistance mechanisms and potential novel targets in the treatment of advanced HCC.

Keywords: hepatocellular carcinoma; immunotherapy; monoclonal antibodies; targeted therapy; tyrosine kinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
A simplified representation of mechanism of action of targeted therapeutics. AKT—protein kinase B; ERK—extracellular signal-regulated kinase; FGFR—fibroblast growth factor receptor; FLT-3—FMS-like tyrosine kinase 3; MEK—mitogen-activated protein kinase; mTOR—mammalian target of rapamycin; PDGFR—platelet-derived growth factor receptor; PI3K—phosphatidylinositol 3-kinase; RAF—rapidly accelerated fibrosarcoma; RAS—rat sarcoma virus; VEGFR—vascular endothelial growth factor receptor.
Figure 2
Figure 2
A timeline of selected phase 2/3 HCC trials published after 2015.
See this image and copyright information in PMC

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F., Bsc M.F.B., Me J.F., Soerjomataram M.I., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Villanueva A. Hepatocellular Carcinoma. N. Engl. J. Med. 2019;380:1450–1462. doi: 10.1056/NEJMra1713263. - DOI - PubMed
    1. Reig M., Forner A., Rimola J., Ferrer-Fàbrega J., Burrel M., Garcia-Criado Á., Kelley R.K., Galle P.R., Mazzaferro V., Salem R., et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol. 2022;76:681–693. doi: 10.1016/j.jhep.2021.11.018. - DOI - PMC - PubMed
    1. Du Z., Lovly C.M. Mechanisms of receptor tyrosine kinase activation in cancer. Mol. Cancer. 2018;17:58. doi: 10.1186/s12943-018-0782-4. - DOI - PMC - PubMed
    1. Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer. 2011;2:1097–1105. doi: 10.1177/1947601911423031. - DOI - PMC - PubMed

MeSH terms